Shandong GeneLeuk Biopharmaceutical Co., Ltd
| About us | All the buildings and equipment were designed and constructed according to the GMP standard of FDA. GeneLeuk passed the GMP certificate of State Drug Administration of China in 1999. In the R&D, manufacturing, marketing and sales of new drugs, GeneLeuk conforms with the international standard of GLP, GCP and GMP. R&D center of GeneLeuk is located in Long Island, New York, USA. Pilot production and manufacture bases are in JiNan City, China. Sales & marketing center is in Beijing City of China. Its product on the market is Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF or Filgrastim) with the trade mark of GeneLeukim . rhG-CSF is a haematopoietic growth factor which principally regulates the formation and development of neutrophiles within the bone marrow and stimulates their release into the peripheral circulation. GeneLeukim is indicated to decrease the incidence of infection as manifested by neutropenia in patients with malignancies receiving myelosuppression anti-cancer drugs associated with a significant incidence of severe neutropenia. For high-dose chemotherapy, GeneLeukim makes chemotherapy safer and more effective as well as reduces antibiotics use duration and hospitalization costs. Products under R&D are the followings: rhPA (Recombinant Human Plasminogen Activator), rh-albumin and long-acting rhG-CSF. The long-acting rhG-CSF has entered into Clinical Trials. The product rhSOD bulk (Superoxide Dismutase) is available now. |
|---|---|
| Industry Focus | Bio-technology Products |
| Business Type | Manufacturer |
| Products/Services | Recombinant Human Granulocyte Colony-stimulating Factor or Filgrastim or rhG-CSF;Recombinant Human Superoxide Dismutase or rhSOD |
| Our Markets | Worldwide |
| No. of Employees | 51 - 100 People |
| Annual Sales Range(USD) | US$2.5 Million - US$5 Million |
| Year Established | 1994 |
| Certificates | GMP Certificate |
